Evaluating Liraglutide in Alzheimer's Disease

NCT01843075 · Unknown status

Last updated 2026-05-28

This clinical trial is testing the effects of the medication liraglutide in people with Alzheimer's disease to see how it impacts brain glucose metabolism.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 204 people

Who can join Ages 50+ · all sexes

Timeline Started 2014-01 · est. completion 2019-12

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT01843075 ↗

Description as written by the study sponsor.

This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD). Patients will be randomised on a 1:1 ratio to receive liraglutide or matching placebo.

Treatments tested

Liraglutide also known as Victoza Drug

Daily subcutaneous injection
Placebo Drug

Daily subcutaneous injection

Main thing measured	The change in cerebral glucose metabolic rate
Sponsor	Imperial College London
Conditions studied	Alzheimer's Disease
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01843075 ↗